Company Overview and News
As per North Dakota’s oil regulator, the state’s daily crude output rose 3.4% in July after edging down 1.6% in the previous month. The North Dakota Department of Mineral Resources’ (‘DMR’) latest data said that oil production in July averaged a record 1,269,366 barrels a day, up 42,046 barrels a day from June. To put this in perspective, oil supplies from the state of North Dakota is now at par with the struggling OPEC producer Venezuela.
ENBBF WLL PSX CTLR MALRY ENB MPC MIN ENB ETP OAS EBBNF CLR MALRF
Investors in Oasis Petroleum Inc. (OAS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $10.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
2018-09-12 zacks - 1
Estimates for Oasis Midstream Partners LP (OMP - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 4.6% and 8.9% north to $1.82 and $2.91, respectively. Units of Oasis Midstream have rallied nearly 28.9% over a year compared with its industry’s growth of 1.3%. Oasis Midstream, a growth-oriented, fee-based master limited partnership formed by Oasis Petroleum Inc.
OMP TCP OAS SOI
2018-09-05 zacks - 1
A month has gone by since the last earnings report for Oasis Petroleum (OAS - Free Report) . Shares have added about 2.1% in that time frame, outperforming the S&P 500.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Altria (MO) and Charter Communications (CHTR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
MIK GLW CHTR REGN OAS TGI MOH UMBF OUT
Chicago, IL – August 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Zynga (ZNGA - Free Report) , Disney (DIS - Free Report) and 21st Century Fox (FOXA - Free Report) .
SOJA HD SO STZ.B WLL CTLR STZ DLTR ZNGA ETP OAS 7018 CME SRE CLR TAST
Chicago, IL – August 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apple (AAPL - Free Report) , Alphabet (GOOGL - Free Report) , Tesla (TSLA - Free Report) , Xilinx (XLNX - Free Report) and NetApp (NTAP - Free Report) .
SOJA XLNX HD SO STZ.B WLL CTLR STZ DLTR BRK.A ETP OAS 7018 CME GOOGL SRE AAPL NTAP CLR TAST
Chicago, IL – August 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Energy Transfer Partners L.P. (ETP - Free Report) , Phillips 66 (PSX - Free Report) , Oasis Petroleum Inc. (OAS - Free Report) , Whiting Petroleum Corp.
SOJA HD STZ.B TXN PSX MALRY MIN DLTR CME TAST SO JELD WLL CTLR STZ ETP OAS 7018 SRE CLR MALRF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to OAS / Oasis Petroleum Inc. on message board site Silicon Investor.
as of ET